Track 9 Meters Biopharma's long-term debt ($35K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2023), NMTR shows a long-term debt of $35K. That compares with $98K in the prior-year period — down 64.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NMTR's long-term debt is now $35K (was $98K) — a 64.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether 9 Meters Biopharma is outperforming or lagging.
Tracking NMTR's long-term debt over time shows whether 9 Meters Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $35K That compares with $98K in the prior-year period — down 64.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has 9 Meters Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $35K) with ownership activity and broader fundamentals.
9 Meters Biopharma's long-term debt is $35K; compare it with other Technology names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.